Resha** the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
Single-and multifraction stereotactic radiosurgery dose/volume tolerances of the brain
Purpose As part of the American Association of Physicists in Medicine Working Group on
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …
Treatment for brain metastases: ASCO-SNO-ASTRO guideline
MA Vogelbaum, PD Brown, H Messersmith… - 2022 - academic.oup.com
Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …
Management of brain metastases according to molecular subtypes
The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Background and purpose While the combination of stereotactic radiosurgery (SRS) and
immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain …
immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain …
State of the art in combination immuno/radiotherapy for brain metastases: systematic review and meta-analysis
Objectives: Common origins for brain metastases (BMs) are melanoma, lung, breast, and
renal cell cancers. BMs account for a large share of morbidity and mortality caused by these …
renal cell cancers. BMs account for a large share of morbidity and mortality caused by these …
Immunotherapy: an emerging modality to checkmate brain metastasis
The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is
nothing less than a death sentence, with few treatment options for palliation or prolonging …
nothing less than a death sentence, with few treatment options for palliation or prolonging …
Current multidisciplinary management of brain metastases
Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of
patients with late‐stage cancer and traditionally are associated with a poor prognosis. The …
patients with late‐stage cancer and traditionally are associated with a poor prognosis. The …
Checkpoint blockade in lung cancer with driver mutation: choose the road wisely.
A Calles, JW Riess, JR Brahmer - American Society of Clinical …, 2020 - europepmc.org
Immune checkpoint blockade with PD-(L) 1 antibodies has revolutionized the treatment of
advanced non-small cell lung cancer (NSCLC). Similarly, the identification and targeting of …
advanced non-small cell lung cancer (NSCLC). Similarly, the identification and targeting of …
Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study
OBJECTIVE Immune checkpoint inhibitors (ICIs) improve survival in patients with advanced
non–small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients …
non–small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients …